Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.

An additional limitation of the study is that in most subgroups we had very limited power to detect highly significant associations, particularly for small to moderate effect sizes (HRs 1.05–1.30), even for variants of relatively high minor allele frequency (MAF = 0.20).

also in 132,142 other papers